Dosage forms of rofecoxib and related methods
AssigneeTremeau Pharmaceuticals, Inc.
InventorsBradford C. Sippy, Raymond D. Skwierczynski, Travis E. Helm
Life of this patent
Estimating the term…
Abstract
The subject matter disclosed herein relates to novel doses and dosage forms of rofecoxib having a therapeutic benefit.
Claims28
A method for treating pain, fever, or inflammation in a human subject, the method comprising orally administering to the subject once daily a solid dosage formulation comprising 17.5 mg of rofecoxib, wherein the formulation achieves a mean Cmax plasma concentration of more than 180 ng/ml following oral administration of a single dose of the formulation to a population of healthy adults less than 65 years of age.
A method for treating pain, fever, or inflammation in a human subject, the method comprising orally administering to the subject once daily a solid dosage formulation comprising 17.5 mg of rofecoxib, wherein the formulation achieves a mean plasma AUC0-∞ of more than 3000 h*ng/ml following oral administration of a single dose of the formulation to a population of healthy adults less than 65 years of age.
A method for treating pain, fever, or inflammation in a human subject, the method comprising orally administering to the subject once daily a solid dosage formulation comprising 17.5 mg of rofecoxib, wherein the formulation achieves an arithmetic mean plasma concentration of at least 2.0 ng/ml at 15 minutes following oral administration of a single dose of the formulation to a population of healthy adults less than 65 years of age.
Dependencies are inferred from the claim text.